LY139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese Subjects.

Trial Profile

LY139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Atomoxetine (Primary)
  • Indications Anxiety disorders; Attention-deficit hyperactivity disorder; Fetal alcohol syndrome; Huntington's disease; Social phobia
  • Focus Pharmacokinetics
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Nov 2016 Primary endpoint (Area Under the Curve From Time Zero to Last Quantifiable Concentration [AUC (0-tlast)]) has been met, according to results published in the Clinical Drug Investigation.
    • 01 Nov 2016 Primary endpoint (Maximum Observed Plasma Concentration (Cmax)) has been met, according to results published in the Clinical Drug Investigation.
    • 01 Nov 2016 Results published in the Clinical Drug Investigation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top